Thrombotic risk factors for atherosclerosis

Coronary Artery Disease

Volumn 7, Issue 12, 1996, Pages 919-932

  Dobroski, David R ^a   Loscalzo, Joseph ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute ischemic syndrome; atherosclerosis; endothelial cell; Factor VII; fibrinogen; fibrinolysis; fibrinolytic system; Lp(a); macrophage; mural thrombus; PAI 1; plaque; platelet; smooth muscle cell; t PA; thrombotic system

Indexed keywords

LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; PROSTACYCLIN;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CORONARY RISK; FIBRINOLYSIS; HUMAN; HYPERINSULINEMIA; LIPOPROTEIN METABOLISM; MACROPHAGE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; THROMBOCYTE; THROMBOGENESIS; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

EID: 0030498957     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199612000-00007     Document Type: Review

References (100)

1. Scharf RE, Harker LA: Thrombosis and atherosclerosis: regulatory role of interactions among blood components and endothelium. Blut 1987, 55:131-144. A review of the interaction of endothelial cells, monocytes, platelets, and vascular smooth muscle cells with humoral hemostatic elements in the process of atherogenesis.
2. Ross R: The pathogenesis of atherosclerosis: perspective for the 1990s. Nature 1993, 362:801-809. A review of recent insights into atherosclerosis, focusing on the role of growth factors, cytokines, and vasoregulatory molecules in the inflammatory fibroproliferative response to various forms of insult to the endothelium and smooth muscle of the vascular wall.
3. Rokitansky K: A Manual of Pathological Anatomy. London: Sydenham Society; 1852:271-273. Rokitansky's seminal text, in which the first theory to explain the process of atherosclerosis was advanced, later to become known as the encrustation theory of atherosclerosis.
4. Collen D, Juhan-Vague I: Fibrinolysis and atherosclerosis. Semin Thromb Hemost 1988, 14:180-183. A review of the contributions of the fibrinolytic system to atherosclerosis, including a historical survey of earlier theories explaining the atherosclerotic process.
5. Duguid JB: Thrombosis as a factor in the pathogenesis of aortic atherosclerosis. J Pathol Bacteriol 1946, 58:207-212. Duguid's foundational exegesis, in which he advanced and defined the role of thrombosis in the pathogenesis of atherosclerosis.
6. Virchow RLK: Cellular pathology as based upon physiological and pathological histology. (Translated from the second German edition by F. Chance). New York: Dover Publications; 1971:230. Virchow's landmark text, in which he first advanced the theory that blood lipids contribute to the genesis of atheromata by accumulating in the vessel wall and inducing intimai proliferation.
7. Ross R, Glomset JA: The pathogenesis of atherosclerosis. N Engl J Med 1976, 295:369-377, 420-425. A review of the earlier theories of the atherosclerotic process, as well as what was the current state of knowledge regarding atherosclerotic lesion pathogenesis, focusing on the role of smooth muscle cells.
8. Ross R: The pathogenesis of atherosclerosis - an update. N Engl J Med 1986, 314:488-500. An update to Ross's previous work, outlining subsequent advances made in explaining the atherosclerotic process, focusing on the cellular constituents of atherosclerosis and their interactions in lesion formation during hypercholesterolemia.
9. Steinberg D, Parthasarathy S, Corew TE, Khoo JC, Witztum JL: Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924. A review of the role of LDL in the process of atherosclerosis, focusing on the oxidative modification of LDL, which increases its atherogenicity.
10. Marcus AJ, Safier LB, Hajjar KA, Ullman HL, Islam N, Broekman MJ, Eiroa AM: Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells. J Clin Invest 1991, 88:1690-1696. A study asserting that aspirin-treated platelet inhibition in the presence of aspirin-treated endothelial cells is mediated in large part by ecto-ADPase activity on endothelial cells.
11. Nawroth PP, Kisiel W, Stern DM: The role of endothelium in the homeostatic balance of haemostasis. Clin Haematol 1985, 14:531-546. A discussion of the role played by endothelial cells in endogenous anticoagulant and procoagulant reactions.
12. Levine JD, Harlan JM, Harker LA, Joseph ML, Counts RB: Thrombin-mediated release of Factor VIII antigen from human umbilical vein endothelial cells in culture. Blood 1982, 60:531-534. An examination of the effects of alpha-thrombin on factor VIII antigen release by human umbilical vein endothelial cells in culture, focusing on the mechanism behind the release of preformed factor VIII antigen.
13. Stern DM, Drilling M, Kiesel W, Nawroth PP, Nossel HL, La Gamma KS: Activation of Factor IX bound to cultured bovine aortic endothelial cells. Proc Natl Acad Sci USA 1984, 81:913-917. Study demonstrating that endothelial cells can bind and promote the activation of Factors IX and X in the absence of platelets or exogenous phospholipid.
14. Nawroth PP, Handly DA, Esmon CT, Stern DM: Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986, 83:3460-3464. Study demonstrating that interleukin-1, a mediator of the inflammatory response, can shift the balance of procoagulant and anticoagulant reactions on the endothelium unidirectionally, favoring clot formation.
15. Kapiotis S, Besemer J, Bevec D, Valent P, Bettelheim P, Lechner K, et al.: Interleukin-4 counteracts pyrogen-induced downregulation of thrombomodulin in cultured human vascular endothelial cells. Blood 1991, 78:410-415. Study showing that interleukin-4 helps protect the endothelial cell surface against pyrogen-induced procoagulant changes, principally through transcriptional regulatory mechanisms.
16. 1 inhibit monocyte procoagulant activity in vitro. Blood 1991, 78:382-386. Study demonstrating that prostacyclin may be a physiologic modulator of monocyte tissue factor expression, and that prostaglandin EI, along with its stable analog, iloprost, are able to inhibit the monocyte-induced procoagulant response of peripheral blood to endotoxin.
17. Tipping PG, Malliaros J, Holdsworth R: Procoagulant activity expression by macrophages from atheromatous vascular plaques. Atherosclerosis 1989, 79:237-243. Studies demonstrating that macrophages within carotid artery plaques have augmented procoagulant activity compared with blood monocytes and macrophages from other atherosclerotic lesions, and that macrophage procoagulant activity may contribute to thrombus formation on ulcerated plaques.
18. Vassalli JD, Dayer JM, Wohlwend A, Belin D: Concomitant secretion of prourokinase and of a plasminogen activator specific inhibitor by cultured human monocytes-macrophages. J Exp Med 1984, 159:1653-1658. The results of this study suggest that plasminogen activation by mononuclear phagocytes can be modulated through the monocyte secretion of both a (pro) enzyme and a specific inhibitor.
19. Hart PH, Burgess DR, Vitti GF, Hamilton JA: Interleukin-4 stimulates human monocytes to produce tissue-type plasminogen activator. Blood 1989, 74:1222-1225. Study showing that interleukin-4, but not interferon-gamma, elevates t-PA messenger RNA expression and secretion of t-PA by human monocytes.
20. Simon DI, Ezratty AM, Francis SA, Rennke H, Loscalzo J: Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. Blood 1993, 82:2414-2422. Study demonstrating that fibrinogen is internalized and degraded by activated human monocytoid cells via the Mac-1 receptor in the absence of plasmin, thereby providing an alternative fibrinolytic pathway.
21. Simon DI, Ezratty AM, Loscalzo J: The fibrin(ogen)olytic properties of cathepsin D. Biochemistry 1994, 33:6555-6563. Study examining the fibrinolytic properties of cathepsin D, a lysosomal aspartyl protease, and reporting that cathepsin D possesses both fibrinogenolytic and fibrinolytic activity, with a discussion of the biochemical characteristics of these reactions.
22. Rabbani LE, Loscalzo J: Recent observations on the role of hemostatic determinants in the development of atherothrombotic plaque. Atherosclerosis 1994, 105:1-7. A discussion of the roles played by a variety of hemostatic determinants, including platelets, lipoprotein(a), and fibrinogen, in the evolution of the atherothrombotic plaque.
23. Schaub RG, Bree MP, Hayes LL, Rudd MA, Rabbani LE, Loscalzo J, et al.: Recombinant human macrophage colony stimulating factor reduces plasma cholesterol and carrageenan granulaoma foam cell formation in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 1994, 14:70-76. Study demonstrating that long-term administration of recombinant human macrophage colony stimulating factor reduces plasma cholesterol and macrophage-derived foam cell development in the Watanabe heritable hyperlipidemic rabbit.
24. Gown AM, Tsukada T, Ross R: Human atherosclerosis II. Immunohistochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol 1986, 125:191-207. An analysis of the distribution of various cell types, including smooth muscle cells, lymphocytes, endothelial cells, and macrophages, in human atherosclerotic plaques using immunocytochemical investigations.
25. Thompson WD, Smith EB: Atherosclerosis and the coagulation system. J Pathol 1989, 159:97-106. A review of the role of the thrombotic system in the genesis of atherosclerotic plaque, focusing on the response of various cellular components to the presence of fibrin-rich thrombus on the vessel wall.
26. Gianella-Neto D, Kamyar A, Forrester JS, Fagin JA: Platelet-derived growth factor isoforms induce insulin-like growth factor-1 gene expression and the production of its binding protein in rat smooth muscle cells. Circulation 1990, 82 (suppl III):208. Study showing that platelet-derived growth factor can stimulate smooth muscle cell proliferation via the induction of insulin-like growth factor-1.
27. Majack RA, Milbrandt J, Dixit VM: Induction of thrombospondin messenger RNA levels occurs as an immediate primary response to platelet-derived growth factor. J Biol Chem 1987, 262:8821-8825. Data establishing that mRNA levels for thrombospondin are regulated by platelet-derived growth factor in a manner similar to that of c-myc, c-fos, and other growth-regulatory gene products, and extending previous findings that thrombospondin secretion by smooth muscle cells is dependent upon exposure to platelet-derived growth factor.
28. Siegbahn A, Hammacher A, Westermark B, Heldin CH: Differential effects of the various isoforms of platelet-derived growth factor on the chemotaxis of fibroblasts, monocytes and granulocytes. J Clin Invest 1990, 85:916-920. An investigation of the chemotactic activities of the three different isoforms of PDGF on fibroblasts, monocytes, and granulocytes, showing that the various isoforms of PDGF stimulate and inhibit chemotaxis in an,isoform- and cell type-specific manner.
29. Hosang M, Rouge M, Wipf B, Eggimann B, Kaufman F, Hunziger W: Both homodimeric isoforms of PDGF (AA and BB) have mitogenic and chemotactic activity and stimulate phosphoinositol turnover. J Cell Physiol 1989, 140:558-564. Study demonstrating that distinctions in responsiveness to the different PDGF isoforms are primarily a consequence of the differences in the levels of surface expression of the various isoform-specific receptor types rather than of the differences in the intrinsic activity of these isoforms.
30. Meyer-Ingold W, Eichner W: Platelet-derived growth factor. Cell Biol Intern 1995, 19:389-398. Review discussing the various PDGF isoforms, focusing on the AB heterodimer.
31. Raines EW, Dower SK, Ross R: Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 1989, 243:393-396. Study demonstrating that the mitogenic activity of interleukin-1 for fibroblasts and smooth muscle cells appears to be indirect and mediated by induction of the PDGF A-chain gene.
32. Loscalzo J: The relation between thrombosis and atherosclerosis. Circulation 1992, 86 (suppl III):III95-III99. Discussion of the known associations between the principal determinants of thrombosis and atherosclerosis, the regulation of thrombotic determinants by cytokines and growth factors, and the modulation of thrombotic determinants by atherogenic lipoproteins, especially LP(a).
33. Barger AC, Beeuwkes R III, Lainey LL, Silverman KJ: Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984, 310:175-177. Work using photographs of coronary arteries injected with a silicone polymer, demonstrating the presence of an extensive vasa vasorum in the region of arterial wall surrounding atherosclerotic plaques.
34. Ferrara N, Winer J, Burton T: Aortic smooth muscle cells express and secrete vascular endothelial growth factor. Growth Fact 1991, 5:141-148. Data demonstrating the expression and synthesis of VEGF by cultured aortic smooth muscle cells and suggesting that the 164 amino-acid species is the predominant molecular form of the growth factor secreted by such cells.
35. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Circulation 1995, 92:11-14. Study demonstrating that bFGF may promote angiogenesis both by a direct effect on endothelial cells, and also indirectly by the upregulation of VEGF expression in smooth muscle cells. A synergistic upregulation of VEGF expression was demonstrated by both bFGF and TGF-beta 1 in the presence of hypoxia.
36. Stravi GT, Hong Y, Zachary IC, Breier G, Baskerville PA, Yla-Herttuala S, et al.: Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett 1995, 358:311-315. Investigation showing a synergistic upregulation of smooth muscle cell VEGF expression by PDGF-BB in the presence of hypoxia, suggesting that PDGF-BB and hypoxic conditions act in concert to induce VEGF in the vascular wall during atherosclerotic lesion development.
37. Brogi E, Wu T, Namiki A, Isner JM: Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994, 90:649-652. Data showing that certain indirect angiogenic cytokines, such as PDGF-BB or transforming growth factor-β-1, may act via induction of bFGF and VEGF gene expression in cells residing near endothelial cells in vivo, and that hypoxia constitutes a potent stimulus for VEGF gene expression, but does not regulate bFGF under the same conditions.
38. Castellot JJ, Favreau LV, Karnovsky MJ, Rosenberg R: Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. J Biol Chem 1982, 257:11256-11260. Study demonstrating the ability of platelet heparatinase to release heparin-like species from cultured endothelial cells, which then inhibit the growth of vascular smooth muscle cells in vitro.
39. Geng YJ, Libby P: Evidence for apoptosis in advanced human atheroma. Co-localization with interleukin-1 beta-converting enzyme. Am J Path 1995, 147:251-266. Investigation showing a role for apoptosis in the regulation of cell accumulation during atherogenesis, and suggesting involvement of interleukin-1 beta-converting enzyme in smooth muscle cell death in fibrous regions of complex atheroma and in macrophage death in the lipid-rich core of the lesion.
40. Bennett MR, Evan GI, Schwartz SM: Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995, 95:2266-2274. Study examining apoptosis of smooth muscle cells derived from coronary plaques and demonstrating that apoptosis of human vascular smooth muscle cells is regulated by both specific gene products and local cytokines acting as survival factors.
41. Welch GN, Zhao Z, Loscalzo J, Ravid K: Oxidative stress induces apoptosis in vascular smooth muscle cells that is attenuated by glutathione. J Invest Med 1996, 44:263A. Work demonstrating that oxidative stress and endothelium-derived relaxing factor contribute to smooth muscle cell apoptosis.
42. Hoak JC: Platelets and atherosclerosis. Semin Thromb Hemost 1988, 14:202-205. Discussion of the consequences of the loss of endothelial integrity, and how the blood platelet behaves under these circumstances.
43. Friedman RJ, Stemerman MB, Wenz B, Moore S, Gauldie J, Gent M, et al.: The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. Smooth muscle cell proliferation and re-endothelialization. J Clin Invest 1977, 60:1191-1201. Study designed to investigate the mechanisms involved in fibromusculoelastic lesion formation produced by selective de-endothelialization by the intra-arterial balloon catheter technique in thrombocytopenic rabbits, and demonstrating that proliferation of smooth muscle cells is dramatically inhibited by reduction of circulating platelet numbers.
44. Mendelsohn ME, Loscalzo J: Role of platelets in cholesterol ester formation by U-937 cells. J Clin Invest 1988, 81:62-68. Observations pointing to a new and potentially important role for platelets in atherogenesis and suggesting a mechanism for foam cell formation in the absence of marked hypercholesterolemia.
45. Kowalska MA, Tuszynski GP, Capuzzi DM: Plasma lipoproteins mediate platelet adhesion. Biochem Biophys Res Commun 1990, 172:113-118. Results demonstrating that major circulating lipoproteins can mediate in-vitro platelet adhesion, and that this adhesion occurs via platelet integrin receptors, suggesting that lipoprotein mediated platelet adhesion may play an important role in the progression of atherosclerosis.
46. 2.
47. 2, and respond normally to thrombin.
48. Nichols TC, Bellinger DA, Tate DA, Reddick RL, Read MS, Koch CG, et al.: von Willebrand factor and occlusive arterial thrombus: a study in normal and von Willebrand's disease pigs with diet-induced hypercholesterolemia and atherosclerosis. Arteriosclerosis 1990, 10:449-461. Study using normal and vWD pigs and asserting that vWF is essential for the development of occlusive microthrombus and for the progression of a mixed microthrombus to an occlusive thrombus.
49. Fuster V, Bowie EJW, Lewis JC, Fas DN, Owen CA Jr, Brown AL: Resistance to arteriosclerosis in pigs with von Willebrand's disease. J Clin Invest 1978, 61:722-730. Paper describing the results of consecutive experiments indicating that pigs with impaired platelet-blood vessel interaction in the form of vWD are resistant to the development of atherosclerotic plaques.
50. Ware JA, Heistad DD: Platelet-endothelium interactions. N Engl J Med 1993, 328:628-635. A review of the role of platelet-endothdium interactions in thrombus formation and dissolution, and how vascular diseases can alter these transcellular mechanisms.
51. Vita JA, Treasure CB, Nabel EG: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990, 81:491-497. Study examining the effects of acetylcholine infused into angiographically smooth coronary arteries demonstrating that traditional coronary artery disease risk factors are associated with the loss of endothelium-dependent vasodilatation.
52. Vanhoutte P: Could the absence or malfunction of vascular endothelium precipitate the occurrence of vasospasm? J Mol Cell Cardiol 1986, 18:679-689. Review discussing the role of the endothelium in relaxation of coronary arteries focusing on EDRF and the other neurohumoral mediators involved in this response, and discussing the absence or dysfunction of endothelium as an important element favoring the occurrence of vasospasm.
53. Scwartz CJ, Valente AJ, Kelley JL, Sprague EA, Edwards EH: Thrombosis and the development of atherosclerosis: Rokitansky revisited. Semin Thromb Hemost 1988, 14:189-195. Review discussing the evidence that implicates the organization and incorporation of mural thrombi as a significant component of atherosclerotic plaque growth in humans, focusing on the role of thrombosis in plaque initiation and fatty streak formation and discussing the influence of hypercholesterolemia on thrombi and fibrofatty plaques.
54. Bini A, Fenoglio JJ, Mesa-Tejada R, Kudryk B, Kaplan KL: Identification and distribution of fibrinogen, fibrin and fibrin(ogen) degradation products in atherosclerosis: use of monoclonol antibodies. Arteriosclerosis 1989, 9:109-121. Study using monoclonal antibodies to characterize the composition of atherosclerotic vessels with regard to fibrinogen, fibrin I, fibrin II, and fibrin(ogen) degradation products, and suggesting that increased fibrin formation and degradation may be associated with progression of atherosclerotic disease.
55. Stirk CM, Kochhar A, Smith EB, Thompson WD: Presence of growth-stimulating fibrin-degradation products containing fragment E in human atherosclerotic plaques. Atherosclerosis 1993, 103:159-169. Study using affinity chromatography experiments to demonstrate that the fibrinogen content of aqueous extracts of proliferative atherosclerotic plaques contributes to the activity of smooth muscle proliferation in chick chorioallantoic membrane by forming fibrin on the surface of the chorioallantoic membrane.
56. Smith EB, Keen GA, Grant A, Stirk C: Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990, 10:263-275. Experiments measuring the levels of fibrinogen and fibrinogen/fibrin-related antigen in normal and atherosclerotic intima, and showing that within the intima there is a continuous formation of cross-linked fibrin and continuous fibrinolysis, both processes generating fragments that may have atherogenic properties.
57. Ridker PM, Hennekens CH: Hemostatic risk factors for coronary heart disease. Circulation 1991, 83:1098-1100. Editorial commenting on the limited role of classic risk factors for atherosclerosis in predicting future clinical thrombotic events, and focusing on hemostatic risk factors such as fibnnogen, Factor VII and total white blood cell count as superior predictors of atherosclerosis and acute coronary syndromes.
58. Ernst E: Plasma fibrinogen - independent cardiovascular risk factor. J Int Med 1990, 277:365-372. Review focusing on experimental and epidemiological evidence supporting fibrinogen as a powerful and independent cardiovascular risk factor, and demonstrating that strategies which traditionally lower cardiovascular risk also reduce fibrinogen levels.
59. O'Conner NJ, Cederholm-Williams S, Cotter L: Hypercoagulability and coronary artery disease. Br Heart J 1984, 52:614-616. Study examining hemostatic variables in young men, and demonstrating increased fibrinogen levels and defective fibrinolysis in those subjects with confirmed coronary artery disease.
60. Ernst E, Resch KL: Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993, 118:956-963. Meta-analysis reviewing published data correlating increased fibrinogen levels with the incidence of myocardial infarction, stroke, and peripheral arterial occlusive disease, and confirming the role of fibrinogen as a major cardiovascular risk factor.
61. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al.: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986, ii: 533-537. Principal results of the Northwick Park Heart Study, which correlated elevated levels of Factor VII coagulant activity and plasma fibrinogen with increased risk for subsequent events related to ischemic heart disease.
62. Kannel WB, D'Agostino RB, Belanger AJ: Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987, 113:1006-1010. Subgroup analysis from the Framingham Study demonstrating a strong correlation between cigarette smoking and elevated plasma fibrinogen levels, with fibrinogen levels being elevated in proportion to the amount of cigarettes smoked and being predictive of an increased risk for cardiovascular events.
63. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW: Role of genetic determination at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987, i:1452-1455. Study using restriction fragment length polymorphisms, 91 individuals to investigate the role of genetic variation at the fibrinogen locus in determining plasma fibrinogen levels, and correlating the genotype B2B2 with an increased plasma fibrinogen level compared with the B1B1 and B1B2 genotypes.
64. Balleisen L, Bailey J, Epping PH, Schulte V, van de Loo J: Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population. I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill using and menopause. Thromb Haemost 1985, 54:475-479. Follow-up to previous epidemiological studies correlating fibrinogen, Factor VIIc and Factor VIIIc levels with age, body weight, smoking, alcohol, birth control pill use, and menopause and further correlating levels of these hemostatic factors with blood glucose, uric acid and lipid parameters. The most striking correlations were found with blood glucose, triglycerides and HDL.
65. Merksey C, Wohl H: Changes in blood coagulation and fibrinolysis in rats fed atherogenic diets. Thromb Diathes Haemorrh 1964, 10:295. Study examining the effects of an atherogenic diet on coagulation and fibrinolysis, and demonstrating increased fibrinogen levels in rats fed a high-cholesterol diet compared with controls.
66. Meade TW, North WRS: Population-based distributions of haemostatic variables. Br Med Bull 1977, 33:283-288. Review examining available data regarding the distributions of hemostatic variables in the asymptomatic population, and noting a positive correlation between plasma cholesterol and fibrinogen levels.
67. Letcher RL, Chien S, Pickering TG, Sealey JE, Laragh JH: Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects: role of fibrinogen and concentration. Am J Med 1981, 70:1195-1202. Study examining the relationship between blood pressure and blood viscosity, and demonstrating a direct correlation between blood pressure and blood viscosity among normotensive and hypertensive subjects, with this relationship being due in part to the rheologic effect of an elevated fibrinogen level.
68. Barnes AJ, Locke P, Scudder PR, Dormandy TL, Dormandy JA, Slack J: Is hyperviscosity a treatable component of diabetic microvascular disease? Lancet 1977, ii:789-791. Study examining blood viscosity in diabetic patients and controls, and demonstrating elevated blood viscosity and decreased erythrocyte deformability in the diabetic patients, with the most striking alterations being seen in those diabetic patients with proliferative retinopathy or nephropathy and in those with evidence of myocardial or peripheral ischemia.
69. Ernst E, Weihmayr T, Schmid M, Baumann M, Matrai A: Cardiovascular risk factors and hemorheology: physical fitness, stress and obesity. Atherosclerosis 1986, 59:263-269. Epidemiological study showing an inverse relationship between physical fitness and blood viscosity and a direct correlation between blood viscosity and both psychological stress and obesity, and proposing that accepted cardiovascular risk factors are associated with abnormalities in the rheologic properties of blood.
70. Kannel WB, McNamara T, Hjortland PM: Menopause and the risk of cardiovascular disease. The Framingham Study. Ann Intern Med 1976, 85:447-452. Subgroup analysis from the Framingham Study showing a greater incidence of cardiovascular disease in postmenopausal than premenopausal women, a difference that could not be explained by elevated hemoglobin or cholesterol levels.
71. Ernst E: Influence of regular physical activity on blood rheology. Eur Heart J 1987, 8 (suppl G):59-62. Series of trials examining the effects of regular physical activity on blood rheology using blood and plasma viscosity, hematocrit, and red cell deformability and aggregation as ex-vivo parameters, and demonstrating enhanced blood rheology in athletes.
72. Ernst E, Pietsch L, Eisengerg J, Matrai A: Blood rheology in vegetarians. Br J Nutr 1986, 55:555-560. Study examining blood rheology in vegetarian subjects and comparing measurements of blood and plasma viscosity, packed cell volume, and erythrocyte filterability and aggregation to non-vegetarian controls, and demonstrating lower values for these indices in the vegetarian subjects.
73. Hostmark AT, Bjerkedal T, Kierulf P, Flaten H, Ulshagen K: Fish oil and plasma fibrinogen. BMJ 1988, 297:180-181. Study demonstrating reduced fibrinogen levels in subjects maintained on a diet high in fish oils.
74. Niort G, Nulgarelli A, Casseder M, Pagano G: Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic, hyperfibrinogenemic patients. Atherosclerosis 1988, 71:113-119. Investigation of the effect of bezafibrate in patients with atherosclerotic vasculopathy and hypefibrinogenemia, demonstrating a reduction in plasma fibrinogen levels, blood filterability, fibrinopeptide A, and platelet activation compared with a control group treated with placebo.
75. Miller GJ, Martin JC, Webster J, Wilkes H, Miller NE, Wilkinson WH, et al.: Association between dietary fat intake and plasma Factor VII coagulant activity, a predictor of cardiovascular mortality. Atherosclerosis 1986, 60:269-277. Study demonstrating elevations in plasma Factor VII:C levels in subjects fed a high-fat diet, suggesting an association between increased Factor VII:C levels and postprandial lipemia.
76. Meade TW, Imeson J, Stirling Y: Effects of changes in smoking and other characteristics on clotting factors and the risk of ischemic heart disease. Lancet 1987, ii:986-990. Analysis using data from the Northwick Park Heart Study demonstrating a strong correlation between smoking and plasma fibrinogen levels, an association which also correlated strongly with risk for ischemic heart disease, suggesting that a substantial part of the relation between smoking and ischemic heart disease may be mediated through changes in fibrinogen concentration.
77. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S: A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991, 11:540-546. Analysis of the genetic composition of Factor VII:C in healthy individuals and demonstrating a strong association between lower Factor VII:C levels and the presence of the M2 allele at the Factor VII locus, those individuals being homozygous for the M2 allele having the lowest Factor VII:C levels.
78. Conti P, Bartle L, Barbacane RC, Reale M, Sipe JD: The down-regulation of IL-6-stimulated fibrinogen steady state mRNA and protein levels by human recombinant IL-1 is not PGE2-dependent: effects of IL-1 receptor antagonist (IL-1RA). Mol Cell Biochem 1995, 142:171-178. Study examining the mechanism of interleukin-6-induced fibrinogen synthesis, as well as that of the negative modulating influence of interleukin-1 on interleukin-6-stimulated fibrinogen, focusing on the influence of prostaglandin on these processes.
79. Grimm RH, Neaton JD, Ludwig W, for the Multiple Risk Factor Intervention Trial Research Group: Prognostic importance of the white cell count for coronary, cancer, and all cause mortality. JAMA 1985, 254:1932-1937. Subset analysis from the Multiple Risk Factor Intervention Trial showing a strong association between white blood cell count and risk for coronary heart disease after controlling for other risk factors such as smoking, cholesterol levels, and blood pressure.
80. Juhan-Vague I, Alessi MC, Vague P: Increased plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991, 34:457-462. Study using normal subjects, type 2 diabetic patients, obese subjects, and subjects with angina demonstrating a strong correlation between levels of plasminogen activator inhibitor-1 and fasting plasma insulin, suggesting a possible causative link between insulin resistance and coronary heart disease.
81. Hamsten A: Coagulation factors and hyperlipidaemia. Curr Opin Lipidol 1991, 2:266-271. Study examining the effects of dietary interventions aimed at reducing serum triglyceride levels and demonstrating improved fibrinolytic junction in response to reductions in serum triglycerides, results which were tempered by the fact that weight loss also occurred in those subjects who experienced a reduction on triglycerides.
82. Almer L-O, Janzon L: Low vascular fibrinolytic activity in obesity. Thromb Res 1975, 6:171-175. Analysis demonstrating an inverse correlation between body weight, in the form of obesity, and vascular fibrinolytic activity.
83. Sundell IB, Bahlgren S, Ranby M, Lundin E, Stenling R, Nilsson TK: Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 1989, 3:51-53. Study demonstrating a reduction in plasminogen activator inhibitor levels in response to moderate weight loss. Reductions in plasminogen activator inhibitor levels in these subjects occurred in the absence of significant reductions in plasma triglycerides.
84. Ridker PM, Vaughn DE, Stampfer MJ, Manson JE, Hennekens CH: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993, 341:1165-1168. Study analyzing t-PA levels in healthy individuals from the Physician's Health Study and documenting a strong association between elevated t-PA levels and risk of future myocardial infarction. The association was abolished when adjustments were made for risk factors that affect the progression of atherosclerosis, suggesting that elevations of t-PA antigen are a result, rather than a cause of, atherosclerotic coronary disease.
85. Wang J, Zhen B, Guo Z, Lu Y: Effect of hyperlipidemic serum on lipid peroxidation, synthesis of prostacyclin, and thromboxane by cultured endothelial cells: protective effect of antioxidants. Free Radical Biol Med 1989, 7:243-249. Study examining the effects of hyperlipidemic sera from atherogenic rabbits on cultured endothelial cells demonstrating that different concentrations of sera induced a time- and dose-dependent alteration in the production of prostacyclin and levels of lipid peroxides in endothelial cells, with the decrease in prostacyclin mediated by inactivation of prostacyclin synthetase.
86. Lefer AM: Prostacyclin, high density lipoproteins, and myocardial ischemia. Circulation 1990, 81:2013-2014. Comment regarding the role of prostacyclin in myocardial ischemia, focusing on the various mechanisms whereby prostacyclin interacts with platelets, foam cells, and HDL transport to promote the atherosclerotic process.
87. 2 by HDL may be an important component in its protective role against coronary artery disease.
88. 2 stability.
89. Loscalzo J: Lipoprotein(a): a unique risk factor for atherothrombotic disease. Arteriosclerosis 1990, 10:672-679 Review of the structure and junction of Lp(a), as well as a discussion of the mechanisms underlying the association between Lp(a) and atherogenesis.
90. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kantz JA, Gotto AM Jr: Association of levels of lipoprotein Lp(a) plasma lipids, and other lipoproteins with coronary artery disease documented by coronary angiography. Circulation 1986, 74:758-765. Study measuring plasma levels of Lp(a) in white patients undergoing coronary angiography, demonstrating a strong and independent correlation between elevations in Lp(a) and the presence and severity of atherosclerotic lesions.
91. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein (a) and the risk of myocardial infarction. JAMA 1993, 27:2195-2199. Study using participants in the Physicians' Health Study to examine the associalion between elevated levels of plasma Lp(a) and risk of future myocardial infarction, demonstrating no association between increased levels of Lp(a) and risk of myocardial infarction.
92. Nachman RL, Gavish D, Azrolan N, Clarkson TB: Lipoprotein(a) in diet-induced atherosclerosis in nonhuman primates. Arterioscler Thromb 1991, 11:32-38. Study using immunohistochemistry to examine the accumulation of Lp(a) in atherosclerotic arteries of monkeys with diet-induced atherosclerosis, demonstrating striking accumulations of Lp(a) in atherosclerotic coronary artery lesions compared with normal, nonatherosclerotic arteries.
93. Loscalzo J, Fless GM, Scanu AM: Lipoprotein(a) inhibits fibrin-dependent enhancement of tissue plasminogen activator activity. Blood 1988, 72:374a Study examining the effect of Lp(a) on t-PA, demonstrating that Lp(a) inhibits the fibrin-dependent enhancement of t-PA activity.
94. Scanu AM: Identification of mutations in human apolipoprotein (a) kringle 4-37 from the study of DNA of peripheral blood lymphocytes: relevance to the role of lipoprotein(a) in atherothrombosis. Am J Cardiol 1995, 75:58B-61 B. Using as technique that amplifies the DNA region coding for kringle 4-37 of human apo(a), the investigators identified two mutations which affect the lysine-binding properties of Lp(a) and, thus, the atherothrombogenic potential of Lp(a).
95. Hajjar KA, Gavish D, Breslow JL, Nachman RL: Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989, 339:303-305. Study demonstrating that Lp(a) interferes with endothelial cell fibrinolysis by inhibiting plasminogen binding, and hence, plasmin generation; findings which provide a potential link between Lp(a), impaired cell surface fibrinolysis, and progressive atherosclerosis.
96. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Cheseboro JH: Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 1990, 82 (suppl II):II47-II59. Review of the events surrounding atherosclerotic plaque rupture and thrombotic vessel occlusion, focusing on the type and content of atherosclerotic plaques which predispose them to rupture, as well as a discussion of the thrombotic events correlating with various clinical ischemic syndromes.
97. Davies MJ: A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990, 82 (suppl II):II38-II46. Discussion of the pathologic and cellular features of atherosclerotic plaques, along with a review of the pathophysiology of plaque rupture and thrombus formation, and their correlation with various clinical ischemic syndromes.
98. Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, et al.: Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986, 7:472-478. Definitively established that the severity of coronary atherosclerotic lesions at the time of initial angiography failed to predict accurately future ischemic coronary events in patients with unstable angina.
99. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, et a.: Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988, 12:56-62, Follow-up to earlier work, confirming the inverse relationship between stenosis severity and risk of future ischemic events.
100. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, et al.: Can coronary angiography predict the site of a future myocardial infarction in patients with mild to moderate coronary artery disease? Circulation 1988, 78:1157-1166. Confirmed earlier work establishing the role of lesion severity in predicting future ischemic events in patients with unstable angina.